Global Information
ȸ»ç¼Ò°³ | ¹®ÀÇ | À§½Ã¸®½ºÆ®

¾Æ½Ã¾ÆÅÂÆò¾ç Áö¿ªÀÇ ¾ÏÁø´Ü ½ÃÀå : ¸ÅÃâ ¿¹Ãø, ½ÃÀå Àü·«, °ø±Þ¾÷üÀÇ ½ÃÀå Á¡À¯À² - »õ·Î¿î Á¾¾ç¸¶Ä¿, ±â¼ú, ½ÃÀå ±âȸ

Asia-Pacific Tumor Markers Sales Segment Forecasts for over 40 Tests: A 17-Country Analysis--Supplier Shares and Strategies, Volume and Sales Segment Forecasts, Emerging Tests, Technologies and Opportunities

¸®¼­Ä¡»ç Venture Planning Group
¹ßÇàÀÏ »óǰ ÄÚµå 445419
ÆäÀÌÁö Á¤º¸ ¿µ¹®
°¡°Ý
US $ 9,500 £Ü 11,246,000 DataPack
US $ 14,500 £Ü 17,165,000 PDF by E-mail (Local license)
US $ 23,600 £Ü 27,937,000 PDF by E-mail (Global license)


¾Æ½Ã¾ÆÅÂÆò¾ç Áö¿ªÀÇ ¾ÏÁø´Ü ½ÃÀå : ¸ÅÃâ ¿¹Ãø, ½ÃÀå Àü·«, °ø±Þ¾÷üÀÇ ½ÃÀå Á¡À¯À² - »õ·Î¿î Á¾¾ç¸¶Ä¿, ±â¼ú, ½ÃÀå ±âȸ Asia-Pacific Tumor Markers Sales Segment Forecasts for over 40 Tests: A 17-Country Analysis--Supplier Shares and Strategies, Volume and Sales Segment Forecasts, Emerging Tests, Technologies and Opportunities
¹ßÇàÀÏ : ÆäÀÌÁö Á¤º¸ : ¿µ¹®

¾Æ½Ã¾ÆÅÂÆò¾ç Áö¿ª ±¹°¡(ÃÑ 17°³±¹)ÀÇ ¾ÏÁø´Ü °Ë»ç(Á¾¾ç¸¶Ä¿ °Ë»ç µî) ½ÃÀåÀ» ºÐ¼®ÇßÀ¸¸ç, Áø´Ü ¹æ¹ý °³¿ä, ÇöÀçÀÇ ±â¼ú ¼öÁØ, ÇöÀçÀÇ ÁÖ¿ä Áø´Ü¾à ¹× °Ë»ç ¹æ¹ý, ±¹°¡º°¡¤Áø´Ü ¹æ¹ýº° µ¿Çâ Àü¸Á(ÇâÈÄ 5³â°£), ÁÖ¿ä °ø±Þ¾÷üÀÇ ÇÁ·ÎÆÄÀÏ¡¤Á¦Ç° Æ÷Æ®Æú¸®¿À¡¤»ç¾÷ Àü·«, ÇâÈÄ ½ÃÀå ±âȸ µîÀÇ Á¤º¸¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

1. ¸ñÂ÷ ¹× µµÇ¥

2. ±¹°¡º° ½ÃÀå µ¿Çâ

  • ¹æ±Û¶óµ¥½Ã
  • Áß±¹
  • È«Äá
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • ¹Ì¾á¸¶
  • ´ºÁú·£µå
  • ÆÄŰ½ºÅº
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

3. Á¾¾ç¸¶Ä¿ ºÐ·ù

4. °¢Á¾ ¾Ï/Á¾¾ç¸¶Ä¿¿ë Áø´Ü¾à °³¹ß ¹× Ãâ½Ã »óȲ

  • ACTH °Ë»ç
  • AFP °Ë»ç
  • ¥â-2 ¸¶ÀÌÅ©·Î±Û·ÎºÒ¸° °Ë»ç
  • CA 15-3/27.29 °Ë»ç
  • CA 19-9 °Ë»ç
  • CA-125 °Ë»ç
  • Ä®½ÃÅä´Ñ °Ë»ç
  • CEA °Ë»ç
  • ¿¡½ºÆ®·Î°Õ ¼ö¿ëü °Ë»ç
  • ÇÁ·Î°Ô½ºÅ×·Ð ¼ö¿ëü °Ë»ç
  • Æä¸®Æ¾ °Ë»ç
  • °¡½ºÆ®¸° °Ë»ç
  • HCG °Ë»ç
  • Àν¶¸° °Ë»ç
  • NSE °Ë»ç
  • ÀáÇ÷ °Ë»ç
  • PAP Smear/HPV °Ë»ç
  • PAP °Ë»ç
  • PSA °Ë»ç
  • ¸²ÇÁ±¸ ¼¼ºÐ·ù °Ë»ç(Lymphocyte Subclassification Tests)

5. ¾ÏÁø´ÜÀÇ ÀáÀçÀû ÀÌ¿ë °¡´É¼º

  • »ýÈ­ÇÐÇ¥ÁöÀÚ(Biochemical Marker)
  • ¹ß¾Ï À¯ÀüÀÚ(Oncogenes)
  • ¼ºÀåÀÎÀÚ(Growth Factors)
  • ÄݷδÏÀÚ±ØÀÎÀÚ(Colony Stimulating Factors)
  • ¸²Æ÷Ä«ÀÎ(Lymphokines)
  • ¸é¿ªÁ¶Á÷È­ÇÐ ¿°»ö(Immunohistochemical Stain)
LSH 17.03.06

¡Ø ÀÌ ÆäÀÌÁö¿¡ °ÔÀçµÇ¾î ÀÖ´Â ³»¿ëÀº ÃÖ½ÅÆÇ°ú ¾à°£ Â÷À̰¡ ÀÖÀ» ¼ö ÀÖÀ¸¹Ç·Î ¿µ¹®¸ñÂ÷¸¦ ÇÔ²² ÂüÁ¶ÇÏ¿© Áֽñ⠹ٶø´Ï´Ù. ±âŸ ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇ ¹Ù¶ø´Ï´Ù.

This new 17-country report from LeadingMarketResearch.com is available by country, market segment, section, or individual test.

This report is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic testing market, in evaluating emerging opportunities and developing effective business strategies during the next five years.

The report provides granular market segmentation analysis and forecasts for over 40 tumor markers; profiles leading suppliers and recent market entrants with innovative technologies and products; reviews current and emerging assays; reviews current instrumentation; evaluates emerging technologies; and offers specific opportunities and growth strategies for suppliers.

Rationale

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.

Country Analyses

Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Myanmar, New Zealand, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam

Business Opportunities and Strategic Recommendations

- Specific new product development opportunities with potentially significant market appeal during the next five years.

- Design criteria for new products.

- Alternative market penetration strategies.

- Potential market entry barriers and risks.

Over 200 Current and Emerging Cancer Diagnostic Tests

- Oncogenes - Biochemical Markers - Growth Factors - Colony Stimulating Factors - Hormones - Immunohistochemical Stains - Lymphokines

- ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.

Supplier Shares, Sales and Volume Forecasts

- Sales and market shares of major cancer diagnostic product suppliers in major countries by individual test.

- Five-year test volume and sales forecasts for major cancer diagnostic assays.

Instrumentation Review

- Analysis of major molecular diagnostic and immunodiagnostic analyzers used for cancer testing, including their operating characteristics, features and selling prices.

Technology Assessment

- Assessment of latest technologies and their potential applications for cancer diagnostic testing.

- Review of competing/complementing technologies.

- Companies, universities and research centers developing new cancer diagnostic tests and detection technologies.

Competitive Strategies

- Strategic assessments of major suppliers and start-up firms developing innovative cancer diagnostic technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.

- The companies analyzed in the report include:

- Abbott Agilent Technologies Applied Gene Technologies Arca Biopharma Beckman Coulter/Danaher Becton Dickinson bioMerieux Bio-Rad CellSearch Cepheid Clinical Genomics Decode Genetics DiaSorin Diazyme Eiken Chemical Elitech Group Enzo Biochem Epigenomics Exact Sciences Fujirebio Guided Therapeutics Hologic Janssen Diagnostics Leica Biosystems Kyowa Medex Myriad Genetics OncoLab Ortho-Clinical Diagnostics Panacea Pharmaceuticals PerkinElmer Polymedco Qiagen Quest Diagnostics Roche Scienion Sequenom Siemens Healthineers Takara Bio Theradiag Thermo Fisher Tosoh Vermillion Wako Pure Chemicals

Contains 1,450 pages and 582 tables

Table of Contents

List of Tables

  • Australia Cancer Diagnostic Volume Forecasts by Test
  • Australia Cancer Diagnostics Sales Forecasts by Test
  • Bangladesh Cancer Diagnostic Volume Forecasts by Test
  • Bangladesh Cancer Diagnostics Sales Forecasts by Test
  • China Cancer Diagnostic Volume Forecasts by Test
  • China Cancer Diagnostics Sales Forecasts by Test
  • Hong Kong Cancer Diagnostic Volume Forecasts by Test
  • Hong Kong Cancer Diagnostics Sales Forecasts by Test
  • India Cancer Diagnostic Volume Forecasts by Test
  • India Cancer Diagnostics Sales Forecasts by Test
  • Indonesia Cancer Diagnostic Volume Forecasts by Test
  • Indonesia Cancer Diagnostics Sales Forecasts by Test
  • Japan Executive Summary Table: Total Tumor Marker Test Volume and Sales Forecast by Market Segment
  • Japan, Estimated Cancer Death Rates Per 100,000 Population
  • Japan, Laboratories Performing Tumor Marker Tests by Market Segment
  • Japan, Hospital Laboratories Performing Tumor Marker Tests by Bed Size
  • Japan, Commercial/Private Laboratories Performing Tumor Marker Tests by Annual Test Volume
  • Japan, Total Tumor Marker Testing Volume Forecast by Market Segment
  • Japan, All Market Segments Major Tumor Marker Test Volume Forecast
  • Japan, Hospital Laboratories Major Tumor Marker Test Volume Forecast by Test
  • Japan, Commercial/Private Laboratories Major Tumor Marker Test Volume Forecast
  • Japan, Total Tumor Marker Sales Forecast by Market Segment
  • Japan, All Market Segments Major Tumor Marker Sales Forecast by Test
  • Japan, Hospital Laboratories Major Tumor Marker Sales Forecast by Test
  • Japan, Commercial/Private Laboratories Major Tumor Marker Sales Forecast by Test
  • Japan, ACTH Test Volume and Diagnostics Sales Forecast by Market Segment
  • Japan, AFP Test Volume and Diagnostics Sales Forecast by Market Segment
  • Japan, Beta-2 Microglobulin Test Volume and Diagnostics Sales Forecast by Market Segment
  • Japan, CA 15-3/27.29 Test Volume and Diagnostics Sales Forecast by Market Segment
  • Japan, CA 19-9 Test Volume and Diagnostics Sales Forecast by Market Segment
  • Japan, CA-125 Test Volume and Diagnostics Sales Forecast by Market Segment
  • Japan, Calcitonin Test Volume and Diagnostics Sales Forecast by Market Segment
  • Japan, Cathepsin Test Volume and Diagnostics Sales Forecast by Market Segment
  • Japan, CEA Test Volume and Diagnostics Sales Forecast by Market Segment
  • Japan, Chromogranin Test Volume and Diagnostics Sales Forecast by Market Segment
  • Japan, Colon-Specific Antigen Test Volume and Diagnostics Sales Forecast by Market Segment
  • Japan, Cytokeratins Test Volume and Diagnostics Sales Forecast by Market Segment
  • Japan, Estrogen Receptor Test Volume and Diagnostics Sales Forecast by Market Segment
  • Japan, Ferritin Test Volume and Diagnostics Sales Forecast by Market Segment
  • Japan, Gastrin Test Volume and Diagnostics Sales Forecast by Market Segment
  • Japan, HCG Test Volume and Diagnostics Sales Forecast by Market Segment
  • Japan, Insulin Test Volume and Diagnostics Sales Forecast by Market Segment
  • Japan, Interferons Test Volume and Diagnostics Sales Forecast by Market Segment
  • Japan, Interleukins Test Volume and Diagnostics Sales Forecast by Market Segment
  • Japan, Lymphocyte Subtyping Test Volume and Diagnostics Sales Forecast by Market Segment
  • Japan, NSE Test Volume and Diagnostics Sales Forecast by Market Segment
  • Japan, Nucleolar Test Volume and Diagnostics Sales Forecast by Market Segment
  • Japan, Occult Blood Test Volume and Diagnostics Sales Forecast by Market Segment
  • Japan, Oncogenes Test Volume and Diagnostics Sales Forecast by Market Segment
  • Japan, Pancreatic Oncofetal Antigen Test Volume and Diagnostics
  • Japan, PAP Smear Test Volume and Diagnostics Sales Forecast by Market Segment
  • Japan, Parathyroid Hormone Test Volume and Diagnostics Sales Forecast by Market Segment
  • Japan, Progesterone Receptor Test Volume and Diagnostics Sales Forecast by Market Segment
  • Japan, PAP Test Volume and Diagnostics Sales Forecast by Market Segment
  • Japan, PSA Test Volume and Diagnostics Sales Forecast by Market Segment
  • Japan, S-100 Protein Test Volume and Diagnostics Sales Forecast by Market Segment
  • Japan, Serotonin Test Volume and Diagnostics Sales Forecast by Market Segment
  • Japan, Sialic Acid Test Volume and Diagnostics Sales Forecast by Market Segment
  • Japan, Squamous Cell Carcinoma Antigen Test Volume and Diagnostics Sales Forecast by Market Segment
  • Japan, TDT Test Volume and Diagnostics Sales Forecast by Market Segment
  • Japan, Thymidine Kinase Test Volume and Diagnostics Sales Forecast by Market Segment
  • Japan, Thyroglobulin Test Volume and Diagnostics Sales Forecast by Market Segment
  • Japan, TPA, Test Volume and Diagnostics Sales Forecast by Market Segment
  • Japan, Total Tumor Marker Sales by Major Suppliers
  • Japan, AFP Testing Market Diagnostics Sales by Major Supplier
  • Japan, CA 15-3/27.29 Testing Market Diagnostics Sales by Major Supplier
  • Japan, CA 19-9 Testing Market Diagnostics Sales by Major Supplier
  • Japan, CA 125 Testing Market Diagnostics Sales by Major Supplier
  • Japan, Calcitonin Testing Market Diagnostics Sales by Major Supplier
  • Japan, PAP Testing Market Diagnostics Sales by Major Supplier
  • Japan, PSA Testing Market Diagnostics Sales by Major Supplier
  • Malaysia Cancer Diagnostic Volume Forecasts by Test
  • Malaysia Cancer Diagnostics Sales Forecasts by Test
  • Myanmar Cancer Diagnostic Volume Forecasts by Test
  • Myanmar Cancer Diagnostics Sales Forecasts by Test
  • New Zealand Cancer Diagnostic Volume Forecasts by Test
  • New Zealand Cancer Diagnostics Sales Forecasts by Test
  • Pakistan Cancer Diagnostic Volume Forecasts by Test
  • Pakistan Cancer Diagnostics Sales Forecasts by Test
  • Philippines Cancer Diagnostic Volume Forecasts by Test
  • Philippines Cancer Diagnostic Volume Forecasts by Test
  • Singapore Cancer Diagnostic Volume Forecasts by Test
  • Singapore Cancer Diagnostics Sales Forecasts by Test
  • South Korea Cancer Diagnostic Volume Forecasts by Test
  • South Korea Cancer Diagnostics Sales Forecasts by Test
  • Taiwan Cancer Diagnostic Volume Forecasts by Test
  • Taiwan Cancer Diagnostics Sales Forecasts by Test
  • Thailand Cancer Diagnostic Volume Forecasts by Test
  • Thailand Cancer Diagnostics Sales Forecasts by Test
  • Vietnam Cancer Diagnostic Volume Forecasts by Test
  • Vietnam Cancer Diagnostics Sales Forecasts by Test
  • Tumor Marker Classification
  • Major Companies Developing or Marketing ACTH Tests
  • Major Companies Developing or Marketing AFP Tests
  • Major Companies Developing or Marketing Beta-2 Microglobulin Tests
  • Major Companies Developing or Marketing CA 15-3/27.29 Tests
  • Major Companies Developing or Marketing CA 19-9 Tests
  • Major Companies Developing or Marketing CA 125 Tests
  • Major Companies Developing or Marketing Calcitonin Tests
  • Major Companies Developing or Marketing CEA Tests
  • Major Companies Developing or Marketing Estrogen Receptor Tests
  • Major Companies Developing or Marketing Progesterone Receptor Tests
  • Major Companies Developing or Marketing Ferritin Tests
  • Major Companies Developing or Marketing Gastrin Tests
  • Major Companies Developing or Marketing HCG Tests
  • Major Companies Developing or Marketing Insulin Tests
  • Major Companies Developing or Marketing NSE Tests
  • Major Companies Developing or Marketing Occult Blood Tests
  • Major Companies Developing or Marketing PAP Smear/HPV Tests
  • Major Companies Developing or Marketing PAP Tests
  • Major Companies Developing or Marketing PSA Tests
  • Major Companies Developing or Marketing
  • Lymphocyte Subclassification Tests
  • Biochemical Markers Potential Applications In Cancer Diagnosis
  • Oncogenes Potential Applications In Cancer Diagnosis
  • Major Companies Developing or Marketing Oncogene Tests
  • Growth Factors Potential Applications In Cancer Diagnosis
  • Colony Stimulating Factors Potential Applications in Cancer Diagnosis
  • Lymphokines Potential Applications in Cancer Diagnosis
  • Immunohistochemical Stains Potential Applications in Cancer Diagnosis
Back to Top
ÀüÈ­ ¹®ÀÇ
F A Q